Mimansa Kandhwal, Amarjot Kaur Grewal, Varinder Singh, Heena Khan and Thakur Gurjeet Singh
Background: Drug discovery is a very time-consuming, tedious, and expensive process lasting for about two or more decades. This complexity of the process of drug discovery and the sluggish pace at which new drugs are being discovered draw the attention of scientists to redefine the whole process with the help of drug repurposing. The usage of old drug moieties in any other disorder with all new mechanisms is defined as repurposing. Repurposing of drugs knocks out the pre-clinical phase and related studies to give that molecule a redefined purpose. Data from these studies may be used in discovering newer molecules to save human effort, time, and expenses as well.
Purpose: The complex etiology of depression and resistance to its treatment drive novel discoveries via therapeutic repurposing and pharmacological repositioning to treat this complex disorder. In addition to the reduction of neurotransmitters such as epinephrine and serotonin, additional processes like inflammation, inadequate blood flow, and neurotoxicants are also being examined as possibly implicated mechanisms.
Methods: Data was extensively collected, thoroughly reviewed and analysed from research published in the respective field.
Results: Taking into consideration the aforementioned pathways has led to the development of repurposed drugs that can be used to treat treatment-resistant depression (TRD).
Conclusions: The incorporation of artificial intelligence in drug repurposing may also enhance the chances of its success rate as it deals with data digitalization which is the main core mechanism used in drug repurposing.
Abbruzzese, C., Matteoni, S., Persico, M., Villani, V.,&Paggi, M. G. (2020). Repurposing chlorpromazine in the treatment of glioblastoma multiforme: analysis of literature and forthcoming steps.
Journal of Experimental & Clinical Cancer Research, 39, 1-3.https://doi.org/10.1186/s13046-020-1534-z
Baker, N. C., Ekins, S., Williams, A. J.,& Tropsha, A. (2018). A bibliometric review of drug repurposing.Drug Discovery Today, 23(3), 661-672.https://doi.org/10.1016/j.drudis.2018.01.018
Balasegaram, M., Ritmeijer, K., Lima, M. A., Burza, S., Ortiz Genovese, G., Milani, B., … & Chappuis, F. (2012). Liposomal amphotericin B as a treatment for human leishmaniasis. Expert opinion on emerging drugs, 17(4), 493-510.https://doi.org/10.1517/14728214.2012.748036
Barden, N. (2004). Implication of the hypothalamic–pituitary–adrenal axis in the physiopathology of depression. Journal of Psychiatry and Neuroscience, 29(3), 185-193.
Bayramgürler, D., Karson, A., Özer, C., & Utkan, T. (2013). Effects of long-term etanercept treatment on anxiety-and depression-like neurobehaviors in rats. Physiology & Behavior, 119, 145-148.https://doi.org/10.1016/j.physbeh.2013.06.010
Brent, D., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Keller, M., … & Zelazny, J. (2008). Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. Jama, 299(8), 901-913.https://doi.org/10.1001/jama.299.8.901
Brunoni, A. R., Lopes, M. &F regni, F. (2008). A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. The International Journal of Neuropsychopharmacology, 11(8), 1169-1180.https://doi.org/10.1017/S1461145708009309
Bryan, J. (2011). How minoxidil was transformed from an antihypertensive to hair-loss drug. Pharmaceutical Journal, 287(7663), 137.https://doi.org/10.1211/PJ.2021.1.69888
Cain, R.A., (2007). Navigating the sequenced treatment alternatives to relieve depression (STAR∗ D) study: practical outcomes and implications for depression treatment in primary care. Primary care: Clinics in Office Practice, 34(3):505-519. https://doi.org/10.1016/j.pop.2007.05.006
Cha, Y., Erez, T., Reynolds, I. J., Kumar, D., Ross, J., Koytiger,G., … & Laifenfeld, D. (2018). Drug repurposing from the perspective of pharmaceutical companies.British Journal of Pharmacology,175(2), 168-180.https://doi.org/10.1111/bph.13798
Coppen, A., Shaw, D., Herzberg, B. &Maggs, R. (1967). Tryptophan in the treatment of depression. The Lancet, 290(7527), 1178-1180.https://doi.org/10.1016/S0140-6736(67)91894-6
Cowen, P. J., Parry-Billings, M. &Newsholme, E. A. (1989). Decreased plasma tryptophan levels in major depression. Journal of Affective Disorders, 16(1), 27-31.https://doi.org/10.1016/0165-0327(89)90051-7
Cuijpers, P., Reynolds III, C. F., Donker, T., Li, J., Andersson, G., & Beekman, A. (2012). Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review. Depression and Anxiety, 29(10), 855-864.https://doi.org/10.1002/da.21985
Czumaj, A., Zabielska, J., Pakiet, A., Mika, A., Rostkowska, O., Makarewicz, W., … &Stelmanska, E. (2019). In vivo effectiveness of orlistat in the suppression of human colorectal cancer cell proliferation. Anticancer Research, 39(7), 3815-3822.https://doi.org/10.21873/anticanres.13531
Delgado, P. L. (2000). Depression: the case for a monoamine deficiency. Journal of Clinical Psychiatry, 61(6), 7-11.
Dell’Osso, L., Carmassi, C., Mucci, F. &Marazziti, D. (2016). Depression, serotonin and tryptophan. Current Pharmaceutical Design, 22(8), 949-954.https://doi.org/10.2174/1381612822666151214104826
Dowrick, C. (2009). Beyond depression: a new approach to understanding and management. Oxford University Press, USA.
E Martin, A., A Schober, D., Nikolayev, A., V Tolstikov, V., H Anderson, W., E Higgs, R., … & M Witkin, J. (2017). Further evaluation of mechanisms associated with the antidepressantlike signature of scopolamine in mice. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 16(4), 492-500.
Ebada, M. E. (2017). Drug repurposing may generate novel approaches to treating depression. Journal of Pharmacy and Pharmacology, 69(11), 1428-1436.https://doi.org/10.1111/jphp.12815
Fabbri, C., Kasper, S., Zohar, J., Souery, D., Montgomery, S., Albani, D., … &Serretti, A. (2021). Drug repositioning for treatment-resistant depression: hypotheses from a pharmacogenomic study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 104, 110050.https://doi.org/10.1016/j.pnpbp.2020.110050
Freitas, A. E., Neis, V. B., & Rodrigues, A. L. S. (2016). Agmatine, a potential novel therapeutic strategy for depression. European Neuropsychopharmacology, 26(12), 1885-1899.https://doi.org/10.1016/j.euroneuro.2016.10.013
Gahr, M. (2014). Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks. Current Neuropharmacology,12(5), 387-398.https://doi.org/10.2174/1570159X12999140619122914
Garnock-Jones, K. P., & Keating, G. M. (2009). Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Pediatric Drugs, 11, 203-226.https://doi.org/10.2165/00148581-200911030-00005
Goldberg, J. S., Bell Jr, C. E. & Pollard, D. A. (2014). Revisiting the monoamine hypothesis of depression: a new perspective. Perspectives in Medicinal Chemistry, 6, PMC-S11375.https://doi.org/10.4137/PMC.S11375
Goldstein, I., Burnett, A. L., Rosen, R. C., Park, P. W., &Stecher, V. J. (2019). The serendipitous story of sildenafil: an unexpected oral therapy for erectile dysfunction. Sexual Medicine Reviews, 7(1), 115-128.https://doi.org/10.1016/j.sxmr.2018.06.005
Gurpur, P. B., Liu, J., Burkin, D. J., & Kaufman, S. J. (2009). Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy. The American Journal of Pathology, 174(3), 999-1008.
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23(1), 56.https://doi.org/10.1136/jnnp.23.1.56
Henriksen, K., Christiansen, C., & Karsdal, M. A. (2011). Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning. Drug Discovery Today, 16(21-22), 967-975.https://doi.org/10.1016/j.drudis.2011.06.010
Herbert, J. (2013). Cortisol and depression: three questions for psychiatry. Psychological Medicine, 43(3), 449-469.https://doi.org/10.1017/S0033291712000955
Hillhouse, T. M. & Porter, J. H. (2015). A brief history of the development of antidepressant drugs: from monoamines to glutamate. Experimental and Clinical Psychopharmacology, 23(1), 1.https://doi.org/10.1037/a0038550
Holsboer, F. (2001). Stress, hypercortisolism and corticosteroid receptors in depression: implicatons for therapy.Journal of Affective Disorder, 62(1-2), 77-91.https://doi.org/10.1016/S0165-0327(00)00352-9
Hong, C. T., Chan, L., Hu, C. J., Lin, C. M., Hsu, C. Y., & Lin, M. C. (2017). Tamoxifen and the risk of Parkinson’s disease in female patients with breast cancer in asian people: a nationwide population-based study. Journal of Breast Cancer, 20(4), 356-360. https://doi.org/10.4048/jbc.2017.20.4.356
Howland, R. H. (2013).Mifepristone as a therapeutic agent in psychiatry. Journal of Psychological Nursing and Mental Health Services, 51(6), 11-14. https://doi.org/10.3928/02793695-20130513-01
Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British Journal of Pharmacology, 162(6), 1239-1249.https://doi.org/10.1111/j.1476-5381.2010.01127.x
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., &Arnesen, H. (2002). Warfarin, aspirin, or both after myocardial infarction. New England Journal of Medicine, 347(13), 969-974.https://doi.org/10.1056/NEJMoa020496
Husain, M. I., Chaudhry, I. B., Khoso, A. B., Husain, M. O., Hodsoll, J., Ansari, M. A., … & Young, A. H. (2020). Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. The Lancet Psychiatry, 7(6), 515-527.https://doi.org/10.1016/S2215-0366(20)30138-3
Institute of Health Metrics and Evaluation, 2023. Global Health Data Exchange (GHDx).
Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely,D., Liu, G., … &Reines, S. (2006). Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.Biological Psychiatry, 59(3), 216-223.https://doi.org/10.1016/j.biopsych.2005.07.013
Kerr, J. L., Timpe, E. M., & Petkewicz, K. A. (2010). Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Annals of pharmacotherapy, 44(11), 1777-1785.https://doi.org/10.1345/aph.1P271
Khan, H., Bangar, A., Grewal, A. K., Bansal, P. & Singh, T. G. (2022). Caspase-mediated regulation of the distinct signaling pathways and mechanisms in neuronal survival. International Immunopharmacology, 110, 108951. https://doi.org/10.1016/j.intimp.2022.108951
Kinlein, S.A., Wilson, C.D.,& Karatsoreos, I.N. (2015). Dysregulated hypothalamic–pituitary–adrenal axis function contributes to altered endocrine and neurobehavioral responses to acute stress.Frontiers in psychiatry, 6, 31.https://doi.org/10.3389/fpsyt.2015.00031
Ko, Y. (2020). Computational drug repositioning: current progress and challenges. Applied Sciences, 10(15), 5076. https://doi.org/10.3390/app10155076
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate Jr, C. A. (2019). The influence of ketamine on drug discovery in depression. Drug Discovery Today, 24(10), 2033-2043.https://doi.org/10.1016/j.drudis.2019.07.007
Kupfer, D.J. (2005).The increasing medical burden in bipolar disorder. Jama, 293(20), 2528-2530.10.1001/jama.293.20.2528
Law, G. L., Tisoncik-Go, J., Korth, M. J. &Katze, M. G. (2013). Drug repurposing: a better approach for infectious disease drug discovery?. Current Opinion in Immunology, 25(5), 588-592.https://doi.org/10.1016/j.coi.2013.08.004
Li, J., Yang, R., Xia, K., Wang, T., Nie, B., Gao, K., … & Wang, W. (2018). Effects of stress on behavior and resting-state fMRI in rats and evaluation of Telmisartan therapy in a stress-induced depression model. BMC Psychiatry, 18(1), 1-13.https://doi.org/10.1186/s12888-018-1880-y
Little A. (2009). Treatment-resistant depression. American family physician, 80(2),167-172.
Mann, J. J. (2005). The medical management of depression. New England Journal of Medicine, 353(17), 1819-1834.https://doi.org/10.1056/NEJMra050730
Martinowich, K., Manji, H. & Lu, B. (2007). New insights into BDNF function in depression and anxiety. Nature Neuroscience, 10(9), 1089-1093.https://doi.org/10.1038/nn1971
McGirr, A., Vöhringer, P. A., Ghaemi, S. N., Lam, R. W., & Yatham, L. N. (2016). Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. The Lancet Psychiatry, 3(12), 1138-1146.https://doi.org/10.1016/S2215-0366(16)30264-4
Meyer, J. H., Ginovart, N., Boovariwala, A., Sagrati, S., Hussey, D., Garcia, A., …& Houle, S. (2006). Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Archives of General Psychiatry, 63(11), 1209-1216.https://doi.org/10.1001/archpsyc.63.11.1209
Motaghinejad, M., Farokhi, N., Motevalian, M., & Safari, S. (2020). Molecular, histological and behavioral evidences for neuroprotective effects of minocycline against nicotine-induced neurodegeneration and cognition impairment: Possible role of CREB-BDNF signaling pathway. Behavioural Brain Research, 386, 112597. https://doi.org/10.2174/1871527316666170309142646
Moussaieff, A., Gross, M., Nesher, E., Tikhonov, T., Yadid, G., & Pinhasov, A. (2012). Incensole acetate reduces depressive-like behavior and modulates hippocampal BDNF and CRF expression of submissive animals. Journal of psychopharmacology, 26(12), 1584-1593.https://doi.org/10.1177/0269881112458729
Neumeister, A. (2003). Tryptophan depletion, serotonin, and depression: where do we stand?. Psychopharmacology bulletin, 37(4), 99-115.
Nosengo, N. (2016). New tricks for old drugs. Nature, 534(7607), 314-316.https://doi.org/10.1038/534314a
Nygaard, H. B., van Dyck, C. H., & Strittmatter, S. M. (2014). Fyn kinase inhibition as a novel therapy for Alzheimer’s disease. Alzheimer’s research & therapy, 6, 1-8.https://doi.org/10.1186/alzrt238
Osterloh, I. H. (2004). The discovery and development of Viagra®(sildenafil citrate). In Sildenafil (pp. 1-13). Basel: Birkhäuser Basel.https://doi.org/10.1007/978-3-0348-7945-3_1
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., … &Schatzberg, A. F. (2016). Major depressive disorder. Nature Reviews Disease Primers, 2(1), 1-20. https://doi.org/10.1038/nrdp.2016.65
Palomares, T., Cordero, M., Bruzos-Cidon, C., Torrecilla, M., Ugedo, L., & Alonso-Varona, A. (2018). The neuroprotective effect of conditioned medium from human adipose-derived mesenchymal stem cells is impaired by N-acetyl cysteine supplementation. Molecular Neurobiology, 55, 13-25.https://doi.org/10.1007/s12035-017-0714-0
Palumbo, A., Facon, T., Sonneveld, P., Blade, J., Offidani, M., Gay, F.,… &Harousseau, J. L. (2008). Thalidomide for treatment of multiple myeloma: 10 years later. Blood, The Journal of the American Society of Hematology,111(8), 3968-3977.https://doi.org/10.1182/blood-2007-10-117457
Pariante, C. M. (2017). Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. European Neuropsychopharmacology, 27(6), 554-559. https://doi.org/10.1016/j.euroneuro.2017.04.001
Plotsky, P. M., Owens, M. J., &Nemeroff, C. B. (1998). Psychoneuroendocrinology of depression: hypothalamic-pituitary-adrenal axis. Psychiatric Clinics of North America, 21(2), 293-307.https://doi.org/10.1016/s0193-953x(05)70006-x
Potter, D. E., & Choudhury, M. (2014). Ketamine: repurposing and redefining a multifaceted drug. Drug Discovery Today, 19(12), 1848-1854.https://doi.org/10.1016/j.drudis.2014.08.017
Prabhakar, N. K., Khan, H., Grewal, A. K. & Singh, T.G. (2022). Intervention of neuroinflammation in the traumatic brain injury trajectory: In vivo and clinical approaches. International Immunopharmacology, 108, 108902.https://doi.org/10.1016/j.intimp.2022.108902
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., … & Pirmohamed, M. (2019).Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery,18(1), 41-58.https://doi.org/10.1038/nrd.2018.168
Pytka, K., Młyniec, K., Podkowa, K., Podkowa, A., Jakubczyk, M., Żmudzka, E., … &Filipek, B. (2017). The role of melatonin, neurokinin, neurotrophic tyrosine kinase and glucocorticoid receptors in antidepressant-like effect. Pharmacological Reports, 69(3), 546-554. https://doi.org/10.1016/j.pharep.2017.01.026
Randolph, M., &Tosti, A. (2021). Oral minoxidil treatment for hair loss: A review of efficacy and safety. Journal of the American Academy of Dermatology, 84(3), 737-746.https://doi.org/10.1016/j.jaad.2020.06.1009
Rascol, O., Fabbri, M., &Poewe, W. (2021). Amantadine in the treatment of Parkinson’s disease and other movement disorders. The Lancet Neurology, 20(12), 1048-1056.https://doi.org/10.1016/S1474-4422(21)00249-0
Rihal, V., Kaur, A., Singh, T. G. & Abdel-Daim, M. M. (2022). Therapeutic and mechanistic intervention of vitamin D in neuropsychiatric disorders. Psychiatry Research, 114782.https://doi.org/10.1016/j.psychres.2022.114782
Rodriguez, J.M., Monsalves-Alvarez,M., Henriquez, S., Llanos, M.N.,&Troncoso, R. (2016). Glucocorticoid resistance in chronic diseases. Steroids, 115,182-192. https://doi.org/10.1016/j.steroids.2016.09.010
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., … & Fisher, P. B. (2005). β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 433(7021), 73-77.https://doi.org/10.1038/nature03180
Schildkraut, J.J. (1965).The catecholamine hypothesis of affective disorders: a review of supporting evidence.American Journal of Psychiatry, 122(5), 509-522.https://doi.org/10.1176/ajp.122.5.509
Souery, D., Papakostas, G. I., & Trivedi, M. H. (2006). Treatment-resistant depression. Journal of Clinical Psychiatry, 67, 16.
Taylor, C., Fricker, A.D., Devi, L.A.,& Gomes, I. (2005). Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways.Cellular Signaling, 17(5), 549-557.https://doi.org/10.1016/j.cellsig.2004.12.007
Teo, S. K., Resztak, K. E., Scheffler, M. A., Kook, K. A., Zeldis, J. B., Stirling, D. I., & Thomas, S. D. (2002). Thalidomide in the treatment of leprosy. Microbes and Infection, 4(11), 1193-1202.https://doi.org/10.1016/s1286-4579(02)01645-3
Tripathy, S., Dassarma, B., Roy, S., Chabalala, H.,&Matsabisa, M. G. (2020). A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. International Journal of Antimicrobial Agents, 56(2), 106028.https://doi.org/10.1016/j.ijantimicag.2020.106028
Tsao, C. W., Lin, Y. S., Chen, C. C., Bai, C. H. & Wu, S. R. (2006). Cytokines and serotonin transporter in patients with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(5), 899-905.https://doi.org/10.1016/j.pnpbp.2006.01.029
Weilburg, J. B. (2004). An overview of SSRI and SNRI therapies for depression. Managed Care (Langhorne, Pa.), 13(6 Suppl Depression), 25-33.
Wilkes, S. (2008). The use of bupropion SR in cigarette smoking cessation. International Journal of Chronic Obstructive Pulmonary Disease, 3(1), 45-53. https://doi.org/10.2147/copd.s1121
Yang, T., Nie, Z., Shu, H., Kuang, Y., Chen, X., Cheng, J., … & Liu, H. (2020). The role of BDNF on neural plasticity in depression. Frontiers in Cellular Neuroscience, 14, 82.https://doi.org/10.3389/fncel.2020.00082
You, H., Lu, W., Zhao, S., Hu, Z., & Zhang, J. (2013). The relationship between statins and depression: a review of the literature. Expert Opinion on Pharmacotherapy, 14(11), 1467-1476.https://doi.org/10.1517/14656566.2013.803067
Zhang, Q. Q., Li, W. S., Liu, Z., Zhang, H. L., Ba, Y. G., & Zhang, R. X. (2020). Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: a meta-analysis and systematic review. Medicine, 99(10).https://doi.org/10.1097/MD.0000000000019378
Zhao, K., & So, H. C. (2018). Drug repositioning for schizophrenia and depression/anxiety disorders: a machine learning approach leveraging expression data. IEEE journal of Biomedical and Health Informatics, 23(3), 1304-1315.https://doi.org/10.1109/JBHI.2018.2856535
Zheng, W., Sun, W. &Simeonov, A. (2018). Drug repurposing screens and synergistic drug‐combinations for infectious diseases. British Journal of Pharmacology, 175(2), 181-191.https://doi.org/10.1111/bph.13895